On Monday, Stifel adjusted its stock price target for GE HealthCare (NASDAQ:GEHC) Technologies Inc. (NASDAQ: GEHC), increasing it to $102 from the previous $100, while maintaining a Buy rating on the stock. The revision follows the U.S. Food and Drug Administration's approval of GE HealthCare's Flurpiridaz, a novel radiopharmaceutical for myocardial perfusion imaging (MPI) using positron emission tomography (PET).
The FDA's approval of Flurpiridaz was announced Friday evening after the market closed. Flurpiridaz is distinguished by its availability as a pre-made "individual dose," which contrasts with the current standard of on-site dose production. This advancement is poised to offer significant clinical improvements over existing MPI radiopharmaceuticals.
Stifel's positive outlook is informed by recent extensive due diligence, which included discussions with physicians. The findings suggest that Flurpiridaz should be quickly adopted by existing U.S. cardiac PET centers. Furthermore, its availability is expected to broadly expand access to cardiac PET imaging across the United States.
The analyst's note also references key insights from their initial coverage of Flurpiridaz in August 2024 and findings from the September 2024 American Society of Nuclear Cardiology meeting. The approval of Flurpiridaz is seen as a clear incremental positive catalyst for GE HealthCare, likely to enhance the company's growth prospects for 2025, especially given that Flurpiridaz's potential contributions are not yet reflected in consensus numbers.
In other recent news, GE HealthCare, a unit of General Electric Company (NYSE:GE), has received FDA approval for its diagnostic drug, Flyrcado. The drug is designed to detect coronary artery disease (CAD) and is expected to become available in select U.S. markets in early 2025. Brokerage Stifel previously highlighted the drug's clinical advantages, including enhanced imaging quality and improved workflow for healthcare providers.
GE HealthCare has also introduced its latest developments in radiation oncology, designed to streamline the radiation therapy process for clinicians and patients. The company's showcase includes Intelligent Radiation Therapy (iRT) and the Revolution™ RT system, among other technologies.
UBS downgraded GE HealthCare's stock from Neutral to Sell due to potential risks from the Chinese market and a lower growth outlook. However, BTIG upgraded the company's rating from Neutral to Buy due to a favorable outlook for the second half of the year.
GE HealthCare reported Q2 revenues of $4.84 billion and earnings per share of $1.00, nearly matching Wall Street expectations. Despite market headwinds in China, the company maintained its earnings guidance for the year and raised its guidance for adjusted earnings before interest and taxes margin expansion. These are recent developments in GE HealthCare Technologies' operations.
InvestingPro Insights
GE HealthCare Technologies Inc. (NASDAQ: GEHC) is showing strong market performance, aligning with Stifel's optimistic outlook. According to InvestingPro data, the company's stock has demonstrated a robust 35.41% total return over the past year and is currently trading near its 52-week high at 97.29% of that peak. This performance supports the positive sentiment surrounding the FDA's approval of Flurpiridaz.
InvestingPro Tips highlight that GEHC is a "prominent player in the Healthcare Equipment & Supplies industry," which is particularly relevant given the recent FDA approval of its innovative radiopharmaceutical. The company's strong financial position is evident from its profitability over the last twelve months and analysts' predictions of continued profitability this year.
With a market capitalization of $42.01 billion and a P/E ratio of 24.55, GEHC appears to be valued in line with its growth prospects. The company's revenue of $19.52 billion in the last twelve months, coupled with a gross profit margin of 40.96%, suggests a solid financial foundation to support the rollout of Flurpiridaz and capitalize on its potential market expansion.
For investors seeking more comprehensive analysis, InvestingPro offers additional tips and insights, with 6 more tips available for GEHC on the platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.